49 related articles for article (PubMed ID: 21051657)
1. Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique.
Ralph AF; Ager B; Bell ML; Collins IM; Andrews L; Tucker K; O'Reilly N; Phillips KA; Butow P
Springerplus; 2014; 3():264. PubMed ID: 26034659
[TBL] [Abstract][Full Text] [Related]
2. Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction.
Vogel VG
BMC Med; 2015 Mar; 13():63. PubMed ID: 25888872
[TBL] [Abstract][Full Text] [Related]
3. Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.
Meyskens FL; Gerner EW
Cancer Prev Res (Phila); 2011 May; 4(5):628-32. PubMed ID: 21543341
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
LaCroix AZ; Powles T; Osborne CK; Wolter K; Thompson JR; Thompson DD; Allred DC; Armstrong R; Cummings SR; Eastell R; Ensrud KE; Goss P; Lee A; Neven P; Reid DM; Curto M; Vukicevic S;
J Natl Cancer Inst; 2010 Nov; 102(22):1706-15. PubMed ID: 21051656
[TBL] [Abstract][Full Text] [Related]
5. Third-generation SERMs may face uphill battle.
Schmidt C
J Natl Cancer Inst; 2010 Nov; 102(22):1690-2. PubMed ID: 21060064
[No Abstract] [Full Text] [Related]
6. Another selective estrogen-receptor modulator for osteoporosis.
Becker C
N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
[No Abstract] [Full Text] [Related]
7. Lasofoxifene in postmenopausal women with osteoporosis.
Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene therapy in the reduction of fractures.
Cefalu CA
Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
[No Abstract] [Full Text] [Related]
9. Tipping the balance for the primary prevention of breast cancer.
Vogel VG
J Natl Cancer Inst; 2010 Nov; 102(22):1683-5. PubMed ID: 21051657
[No Abstract] [Full Text] [Related]
10. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
11. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
12. [Evidence of raloxifene on postmenopausal osteoporosis].
Okano H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]